Jazz Pharmaceuticals, Inc.
BiotechJazz Pharmaceuticals, Inc. is a biotechnology company focused on Oncology, Neurology, Gastroenterology. Key products include Erwinaze.
Jazz Pharmaceuticals, Inc. at a Glance
- Fast trial execution (21 months median completion)
Upcoming FDA Decisions
Full Calendar →Jazz Pharmaceuticals, Inc.'s Key Drugs
Jazz Pharmaceuticals, Inc.'s core commercial portfolio centers on Erwinaze, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.
Jazz Pharmaceuticals, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Jazz Pharmaceuticals, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
Jazz Pharmaceuticals, Inc.'s Therapeutic Areas
Jazz Pharmaceuticals, Inc.'s approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Jazz Pharmaceuticals, Inc.'s Top Competitors
Jazz Pharmaceuticals, Inc.'s closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Jazz Pharmaceuticals, Inc. Pipeline Snapshot
Jazz Pharmaceuticals, Inc. has 77 active clinical programs from ClinicalTrials.gov — 23 Phase 3, 34 Phase 2 and 20 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Erwinaze leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 27/40 completed
- • Speed: 21 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2011-11-17
- Latest
- 2011-11-17
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges